Paragon 28 Stock News

NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Paragon 28, Inc. (NYSE:FNA)'s sale to Zimmer Biomet Holdings, Inc. for $13.00 per share in cash. Paragon 28 shareholders will also rece...

Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basis Fourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31 Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basis Full-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00 Company p...

NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Paragon 28, Inc. (NYSE: FNA) and its board of directors concerning the proposed acquisition of the company by Zimmer Biomet Holdings, Inc. (NYSE: ZBH). Stockholders will receive $13.00 and a contingent value right for up to $1.00 for each share of Paragon 28 stock that they hold.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. (NYSE: ZBH). Under the terms of the proposed transaction, shareholders of Paragon will receive $13.00 in cash as well as a non-tradeable contingent valu...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. for $13.00 per share in cash is fair to Paragon 28 shareholders. Paragon 28 shareholders will also receive a non-tradeable contingent value right entitling the holder to receive up to $1.00 per share in cash if certain revenu...

Zimmer Biomet said on Tuesday it would acquire medical device company Paragon 28 for about $1.1 billion.

Demonstrates Zimmer Biomet's Commitment to Investing in Higher GrowthEnd-Markets, with Expansion into ~$5 Billion Foot and Ankle Segment Expected to Enhance Zimmer Biomet's Financial Profile; Immediately Accretive to Revenue Growth and Accretive to Adjusted EPS within 24 Months of Deal Close WARSAW, Ind. and ENGLEWOOD, Colo.

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2024. Preliminary unaudited net revenue for the fourth quarter of 2024 is expected to be in a...